The timing was expected; the magnitude of the clinical signal is the new information. Disc had already guided to initial RESTORE-PV data in the third quarter of 2026, so this is not a surprise event on timing. The market was looking for evidence that iron restriction could control hematocrit while reducing patients’ dependence on blood removal—not merely pharmacodynamic proof that DISC-3405 raises hepcidin.
| Metric | RESTORE-PV result | Comparison |
|---|---|---|
| Mean phlebotomy events over 26 weeks | 0.6 | 4.0 during the 26-week baseline period (RESTORE-PV results) |
| Participants phlebotomy-free through 26 weeks | 61.5% | Post-baseline (RESTORE-PV results) |
| Participants phlebotomy-free during first maintenance period | 77.8% | Weeks 12–32; n=9 (RESTORE-PV results) |
| Mean hematocrit | Below 45% | Maintained through week 26 (Other Events) |
| Cohort A completing 26 weeks | 13 patients | Of 20 dosed (Trial design and data cut) |
The efficacy readout clears the practical bar investors were watching. Among the 13 Cohort A patients who completed 26 weeks, mean phlebotomy events dropped from 4.0 to 0.6, while 61.5% stayed completely phlebotomy-free. The filing also reports that mean hematocrit remained stably below 45% through week 26. 〔0〕 〔1〕
The result is meaningful because it connects mechanism to patient-relevant outcomes. The filing shows dose-proportional pharmacokinetics, increased hepcidin, lower serum iron, controlled hematocrit, and fewer phlebotomies rather than stopping at laboratory changes. 〔2〕 That combination is better than a merely in-line mechanistic update and supports continued development toward a pivotal study.
The main limitation is that this is an encouraging early signal, not a definitive Phase 2 verdict. Efficacy is reported for only Cohort A, with 13 patients completing 26 weeks, and the study is open-label with no control arm. Cohort B contributes baseline and safety information but not yet a comparable efficacy dataset. The safety profile was generally acceptable, with mild, self-limited injection-site reactions reported. 〔3〕
Net: better than the standing expectation for an initial data release, while the next update must show durability and broader confirmation. The current evidence supports a positive clinical read, but the valuation-relevant question shifts to whether hematocrit control and phlebotomy reduction persist across more patients, including the every-four-week cohort. Disc plans another RESTORE-PV update and initial sickle-cell data by the end of 2026.
Read the original 8-K on SEC EDGAR ↗